Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Palmitoyl-dipeptide-6

Palmitoyl Dipeptide-6 Diaminohydroxybutyrate, Pal-Lys-Val-Dab

Quick Stats
Studies 98
Trials 0
Score 2
2025 pubmed

Carvacrol alleviates diabetic cardiomyopathy in rats: Targeting Cuproptosis pathway.

Attia. Hala H; Alshanwani. Aliah A; Alatrouzi. Nadin N; Ibrahim. Sara S; Alanteet. Alaa A; Algarzae. Norah K NK; Alonazi. Asma A; Arafah. Maha M; Hasan. Iman I; Ali. Rehab R; Sarawi. Wedad W

Key Findings

  • Carvacrol lowered blood glucose‑related heart injury markers (CK‑MB, troponin‑I, etc.)
  • It normalized cardiac copper levels by decreasing copper import (CTR1) and increasing export proteins (ATP7A/B)
  • Reduced inflammation, lipid peroxides, and oxidative stress while boosting antioxidant defenses (GSH, SOD)

Practical Outcomes

  • Carvacrol shows potential as a heart‑protective supplement for diabetic conditions, likely through copper regulation. Human dosing and safety are not established, so anyone interested should start with low‑dose oregano oil or purified carvacrol and monitor effects, preferably under medical guidance.

Summary

In a rat study, giving carvacrol (a compound found in oregano oil) helped protect the heart from damage caused by diabetes. It lowered harmful heart enzymes, reduced inflammation and oxidative stress, and fixed copper imbalance that leads to a type of cell death called cuproptosis.

Abstract

Diabetic cardiomyopathy (DCM) is a myocardial injury induced by chronic hyperglycemia. Recent literature has reported that hyperglycemia causes cardiac copper overload, triggering copper-induced cell death (cuproptosis). Copper leads to the dysregulation of ferredoxin-1 (FDX-1) and lipoic acid synthase (LIAS), two enzymes essential for the lipoylation process in the Krebs cycle, and are considered key markers of cuproptosis. We aim to explore the protective effects of carvacrol (CAR) against DCM by targeting cuproptosis. Diabetes was induced by a high-fat diet/streptozotocin (35 mg/kg) model. Rats were divided into: normal control, CAR control, diabetic group, and diabetic rats treated with CAR (20 mg/kg) or valsartan (30 mg/kg) for six weeks. The following were assayed: blood glucose, insulin, copper, serum cardiac biomarkers (creatine kinase-MB, cardiac troponin-I, aspartate aminotransferase, and lactate dehydrogenase), lipid peroxides, reduced glutathione (GSH), superoxide dismutase (SOD), inflammatory markers, copper transporter-1 (CTR1, copper importer), ATP7A and ATP7B (copper exporters), heat shock protein-70 (HSP-70), FDX-1 and LIAS. Pathological changes and fibrosis were detected. The diabetic group showed significant increases in serum cardiac biomarkers, cardiac levels of inflammatory cytokines and lipid peroxides, while GSH and SOD decreased. This was accompanied by increased copper, HSP-70, CTR1, and FDX-1, along with reduced ATP7A, ATP7B, and LIAS in cardiac tissues, indicating copper overload and cuproptosis. Histological examination revealed myocardial cell necrosis, nuclear enlargement, and collagen accumulation. Treatment with CAR ameliorated all deviations mentioned above. These findings highlight the cardioprotective effects of CAR against DCM through the normalization of cardiac copper homeostasis and inhibition of cuproptosis.

Study Information

Provider

pubmed

Year

2025

Date

2025-11-11T00:00:00.000Z

DOI

10.1016/j.taap.2025.117636

References

72